Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.

BACKGROUND Radiation safety is an essential component in the treatment of patients with thyroid diseases by ¹³¹I. The American Thyroid Association created a task force to develop recommendations that would inform medical professionals about attainment of radiation safety for patients, family members, and the public. The task force was constituted so as to obtain advice, experience, and methods from relevant medical specialties and disciplines. METHODS Reviews of Nuclear Regulatory Commission regulations and International Commission on Radiological Protection [corrected] recommendations formed the basic structure of the recommendations. Members of the task force contributed both ideas and methods that are used at their respective institutions to aid groups responsible for treatments and that instruct patients and caregivers in the attainment of radiation safety. There are insufficient data on long-term outcomes to create evidence-based guidelines. RESULTS The information was used to compile delineations of radiation safety. Factors and situations that govern implementation of safety practices are cited and discussed. Examples of the development of tables to ascertain the number of hours or days (24-hour cycles) of radiation precaution appropriate for individual patients treated with ¹³¹I for hyperthyroidism and thyroid cancer have been provided. Reminders in the form of a checklist are presented to assist in assessing patients while taking into account individual circumstances that would bear on radiation safety. Information is presented to supplement the treating physician's advice to patients and caregivers on precautions to be adopted within and outside the home. CONCLUSION Recommendations, complying with Nuclear Regulatory Commission regulations and consistent with guidelines promulgated by the National Council on Radiation Protection and Measurement (NCRP-155), can help physicians and patients maintain radiation safety after treatment with ¹³¹I of patients with thyroid diseases. Both treating physicians and patients must be informed if radiation safety, an integral part of therapy with ¹³¹I, is to be attained. Based on current regulations and understanding of radiation exposures, recommendations have been made to guide physicians and patients in safe practices after treatment with radioactive iodine.

[1]  L. Bartalena Diagnosis and management of Graves disease: a global overview , 2013, Nature Reviews Endocrinology.

[2]  C. Edinboro,et al.  Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners. , 2011, Thyroid : official journal of the American Thyroid Association.

[3]  Markus Luster,et al.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  A. Sawka,et al.  Controversies in primary treatment of low-risk papillary thyroid cancer , 2013, The Lancet.

[5]  H. Palmedo,et al.  Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Jack Valentin,et al.  Release of patients after therapy with unsealed radionuclides , 2004, Annals of the ICRP.

[7]  F. Azizi,et al.  Breastfeeding and maternal and infant iodine nutrition , 2009, Clinical endocrinology.

[8]  J. Sisson Response to Beasley CW, Moore WH, and Wagner LK , 2011 .

[9]  M. Mcdermott,et al.  New American Thyroid Association and American Association of Clinical Endocrinologists guidelines for thyrotoxicosis and other forms of hyperthyroidism: significant progress for the clinician and a guide to future research. , 2011, Thyroid : official journal of the American Thyroid Association.

[10]  R. Kloos Survey of radioiodine therapy safety practices highlights the need for user-friendly recommendations. , 2011, Thyroid : official journal of the American Thyroid Association.

[11]  L. Wagner,et al.  Release instructions for hyperthyroid patients treated with I-131. , 2011, Thyroid : official journal of the American Thyroid Association.

[12]  H A Risch,et al.  Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. , 1989, The New England journal of medicine.

[13]  M. Brzozowska,et al.  Timing and Potential Role of Diagnostic I-123 Scintigraphy in Assessing Radioiodine Breast Uptake Before Ablation in Postpartum Women With Thyroid Cancer: A Case Series , 2006, Clinical nuclear medicine.

[14]  A. Holmes,et al.  ABM Clinical Protocol #5: Peripartum breastfeeding management for the healthy mother and infant at term, revision 2013. , 2013, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.

[15]  Shannon D. Sullivan,et al.  Thyroid disorders during pregnancy. , 2012, The Medical clinics of North America.

[16]  J. Siegel,et al.  LICENSEE OVER-RELIANCE ON CONSERVATISMS IN NRC GUIDANCE REGARDING THE RELEASE OF PATIENTS TREATED WITH 131I , 2007, Health physics.

[17]  K. Gulenchyn,et al.  Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy. , 2007, Radiation protection dosimetry.

[18]  D. Gnepp,et al.  Pediatric thyroid cancer after the chernobyl disaster. Pathomorphologic study of 84 cases (1991–1992) from the republic of Belarus , 1994, Cancer.

[19]  C. Buchpiguel,et al.  Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe? , 2009, Nuclear medicine communications.

[20]  J. N. van den Anker,et al.  Safety during breastfeeding: drugs, foods, environmental chemicals, and maternal infections. , 2013, Seminars in fetal & neonatal medicine.

[21]  Stephanie L. Lee Radioactive iodine therapy , 2012, Current opinion in endocrinology, diabetes, and obesity.

[22]  J. Moake,et al.  This article has been cited by other articles , 2003 .

[23]  E. Mazzaferri Empiric Radioactive Iodine Dosing Regimens Frequently Exceed Maximum Tolerated Activity Levels in Elderly Patients with Thyroid CancerTuttle RM, Leboeuf R, Robbins RJ, et al (Mem Sloan-Kettering Cancer Ctr, New York) J Nucl Med 47:1587–1591, 2006§ , 2007 .

[24]  J. Carey,et al.  Release of Patients Containing Therapeutic Dosages of Iodine-131 from Hospitals , 1995 .

[25]  Jyotika K. Fernandes,et al.  Well Differentiated Thyroid Carcinoma: Current Treatment , 2012, Current Treatment Options in Oncology.

[26]  R. Quiros,et al.  To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients , 2012, Journal of oncology.

[27]  A. Gafni,et al.  A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors , 2008, Clinical endocrinology.

[28]  S. Larson,et al.  Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  D. van Nostrand,et al.  Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  A. Turnbull,et al.  Structural and functional development of the human foetal thyroid. , 1966, Clinical science.

[31]  A. Introduction RELEASE OF PATIENTS ADMINISTERED RADIOACTIVE MATERIALS , 1997 .

[32]  P. Grigsby,et al.  Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. , 2000, JAMA.

[33]  A. Gafni,et al.  A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors , 2008, Clinical endocrinology.